Selank

Status

Approved elsewhere. An approved pharmaceutical in Russia. It has no FDA-approved product and no US clinical trial program.

What it is

A heptapeptide based on the immune peptide tuftsin, with an added sequence for stability. Developed alongside semax at Moscow research institutes; studied for anxiety-type indications as a nasal peptide.

Source

Russian pharmaceutical registration; no FDA product

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.